Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The blood-based biomarkers market is witnessing robust growth due to the increasing demand for non-invasive diagnostic solutions and the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. Advances in genomics, proteomics, and liquid biopsy technologies have significantly improved the accuracy and clinical utility of blood-based biomarkers. Growing adoption of precision medicine, expanding biomarker-based drug development, and increasing investments in clinical research are further accelerating market expansion. Additionally, supportive regulatory initiatives and the integration of artificial intelligence in biomarker discovery are expected to drive sustained growth in the coming years.

New York, USA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The blood-based biomarkers market is witnessing robust growth due to the increasing demand for non-invasive diagnostic solutions and the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. Advances in genomics, proteomics, and liquid biopsy technologies have significantly improved the accuracy and clinical utility of blood-based biomarkers. Growing adoption of precision medicine, expanding biomarker-based drug development, and increasing investments in clinical research are further accelerating market expansion. Additionally, supportive regulatory initiatives and the integration of artificial intelligence in biomarker discovery are expected to drive sustained growth in the coming years.

DelveInsight’s Blood-Based Biomarkers Market Insights report provides the current and forecast market analysis, individual leading blood-based biomarker companies’ market shares, challenges, blood-based biomarkers market drivers, barriers, trends, and key blood-based biomarkers companies in the market.

Blood-Based Biomarkers Market Summary

• 2025 Blood-Based Biomarkers Market Size: USD 8.5 Billion
• 2034 Projected Blood-Based Biomarkers Market Size: USD 18.5 Billion
• Blood-Based Biomarkers Market Growth Rate (2026-2034): ~9% 
• Largest Blood-Based Biomarkers Market: North America
• Largest Type Segment: Genetic Biomarkers Category
• Key Companies in the Blood-Based Biomarkers Market: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Quanterix Corporation, Fujirebio Holdings, Inc., Guardant Health, Inc., and others

To read more about the latest highlights related to the blood-based biomarkers news, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/blood-based-biomarkers-market

Key Factors Contributing to the Rise in Growth of the Blood-Based Biomarkers Market

• Rising Prevalence of Chronic Diseases: The increasing incidence of cancer, cardiovascular disorders, neurodegenerative diseases, and metabolic conditions is driving demand for early and accurate diagnostic tools. Blood-based biomarkers enable timely disease detection, monitoring, and risk assessment, supporting improved clinical outcomes.
• Growing Demand for Non-Invasive Diagnostics: Patients and healthcare providers are increasingly favoring minimally invasive diagnostic approaches over traditional tissue biopsies. Blood-based biomarker tests offer a safer, faster, and more convenient alternative, encouraging broader adoption across clinical settings.
• Advancements in Omics and Molecular Technologies: Rapid progress in genomics, proteomics, metabolomics, and transcriptomics has accelerated the discovery and validation of novel blood-based biomarkers. Enhanced analytical platforms such as next-generation sequencing (NGS) and mass spectrometry are improving test sensitivity and accuracy.
• Expansion of Precision Medicine: The growing focus on personalized healthcare is increasing the use of blood-based biomarkers to guide treatment selection, predict therapeutic response, and monitor disease progression. This trend is particularly prominent in oncology and rare disease management.
• Increasing Adoption of Liquid Biopsy Technologies: Liquid biopsy has emerged as a transformative approach for detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from blood samples. Its expanding clinical applications in cancer screening, diagnosis, and treatment monitoring are fueling market growth.
• Rising Investments in Biomarker Research and Development: Pharmaceutical companies, biotechnology firms, and research institutions are investing heavily in biomarker discovery and validation programs. Strategic collaborations and funding initiatives are accelerating the commercialization of innovative blood-based diagnostic solutions.
• Growing Role in Drug Development and Clinical Trials: Blood-based biomarkers are increasingly utilized in clinical trials to identify suitable patient populations, evaluate drug efficacy, and monitor safety. Their ability to improve trial efficiency is encouraging greater adoption by pharmaceutical and biotechnology companies.
• Supportive Regulatory and Healthcare Initiatives: Regulatory agencies are recognizing the clinical value of biomarker-based diagnostics, while governments are promoting early disease detection and precision medicine programs. These initiatives are creating favorable conditions for the adoption and commercialization of blood-based biomarker technologies.
• Increasing Healthcare Expenditure and Diagnostic Awareness: Rising healthcare spending, coupled with greater awareness regarding preventive healthcare and early diagnosis, is boosting the demand for advanced diagnostic tests. This is particularly evident in developed markets and rapidly expanding healthcare systems in emerging economies.
• Integration of Artificial Intelligence and Digital Health: The incorporation of artificial intelligence (AI) and machine learning into biomarker analysis is improving data interpretation, predictive accuracy, and clinical decision-making. AI-enabled platforms are enhancing the efficiency and scalability of blood-based biomarker testing, further supporting market expansion.

Get a sneak peek at the blood-based biomarkers market dynamics @ Blood-Based Biomarkers Market Trends

Regional Blood-Based Biomarkers Market Insights

North America

• North America captured approximately 44% of the global blood-based biomarkers market revenue in 2025, making it the largest regional market worldwide. 
• This leading position is supported by the region's advanced healthcare infrastructure, substantial healthcare expenditure, widespread adoption of innovative diagnostic technologies, and the high prevalence of cancer and neurological disorders. 
• The presence of major diagnostic companies and liquid biopsy innovators, particularly in the United States, further reinforces regional growth. 
• North America continues to lead in regulatory approvals and clinical implementation, highlighted by the 2025 FDA clearance of the first blood-based test for assisting Alzheimer's disease diagnosis, the rapid expansion of nationwide laboratory testing, approvals for plasma tau assays in primary care settings, and earlier authorizations of point-of-care brain injury biomarker tests. 
• In addition, the region benefits from a strong pipeline of oncology and neurology diagnostics, significant research investments, increasing payer support, and clinical guideline endorsements promoting the use of blood-based biomarker testing. 
• These strengths in innovation, regulatory advancement, and healthcare infrastructure are expected to sustain North America's market leadership throughout the forecast period.

Europe

• Europe accounted for a significant share of the global blood-based biomarkers market revenue in 2025, establishing itself as one of the key regional markets worldwide.
• The region's strong market position is supported by its well-developed healthcare systems, broad access to advanced diagnostic services, increasing healthcare expenditure, and the rising prevalence of cancer, cardiovascular diseases, and neurodegenerative disorders.
• The presence of leading pharmaceutical, biotechnology, and diagnostics companies, along with an extensive network of academic research institutions across countries such as Germany, France, the United Kingdom, Italy, and Spain, continues to drive innovation and commercialization of blood-based biomarker technologies.
• Europe remains at the forefront of clinical research and regulatory adoption, supported by expanding implementation of liquid biopsy testing, increasing use of blood-based biomarkers in precision oncology, growing integration of biomarker-guided diagnostics into routine clinical practice, and ongoing collaborations between healthcare providers, research organizations, and industry participants.
• In addition, the region benefits from favorable government funding for biomedical research, expanding personalized medicine initiatives, increasing reimbursement support in several countries, and growing clinical guideline recommendations for biomarker-based disease detection and treatment monitoring.
• These strengths in scientific research, regulatory support, healthcare infrastructure, and precision medicine adoption are expected to sustain Europe's strong position in the blood-based biomarkers market throughout the forecast period.

Asia-Pacific

• Asia-Pacific represents the fastest-expanding regional market for blood-based biomarkers. 
• The region's robust growth is fueled by its large and rapidly aging population, increasing prevalence of cancer, cardiovascular disorders, and neurological diseases, rising healthcare investments, and broader adoption of advanced diagnostic technologies across countries such as China, Japan, India, South Korea, and Australia. 
• Greater awareness of liquid biopsy and other minimally invasive diagnostic approaches, ongoing expansion of laboratory capabilities, supportive government programs promoting early disease detection, and increasing research and diagnostic innovation are further strengthening market growth. 
• Japan continues to play a significant role in advancing blood-based diagnostics for neurodegenerative diseases, while regional companies are introducing more affordable testing solutions. 
• Combined with rising healthcare spending, a growing chronic disease burden, and improved access to diagnostic services, Asia-Pacific is expected to remain the key contributor to incremental market growth throughout the forecast period.

To know more about why North America is leading the market growth in the blood-based biomarkers market, get a snapshot of the Blood-Based Biomarkers Market Share

Recent Developmental Activities in the Blood-Based Biomarkers Market

• In February 2026, Lucent Diagnostics (a Quanterix brand) partnered with Life Line Screening to bring advanced blood-based Alzheimer's disease biomarker diagnostics to community screening events nationwide.
• In October 2025, F. Hoffmann-La Roche Ltd received FDA clearance for its Elecsys pTau181 test, a blood-based biomarker test indicated as an adjunct in early evaluation for Alzheimer's disease and cognitive impairment in the primary-care setting. 
• In August 2025, Laboratory Corporation of America Holdings launched the FDA-cleared Alzheimer's plasma biomarker blood test nationwide, broadening patient access across the United States.
• In May 2025, Fujirebio Holdings, Inc., received FDA 510(k) clearance for its Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based in vitro diagnostic in the United States to aid identification of amyloid pathology associated with Alzheimer's disease.

What are Blood-Based Biomarkers?

Blood-based biomarkers are measurable biological molecules present in the bloodstream that provide valuable information about normal physiological processes, disease development, progression, and response to treatment. These biomarkers may include proteins, nucleic acids (such as circulating DNA and RNA), metabolites, lipids, hormones, extracellular vesicles, and circulating cells, all of which can reflect changes occurring within the body. Because they can be detected through minimally invasive blood samples, blood-based biomarkers have become increasingly important in clinical diagnostics, disease screening, prognosis, patient stratification, and therapeutic monitoring. They play a critical role across a wide range of therapeutic areas, including oncology, cardiovascular diseases, neurological disorders, infectious diseases, and autoimmune conditions, enabling earlier diagnosis, more personalized treatment strategies, and real-time assessment of disease status while reducing the need for invasive tissue biopsies.

Blood-Based Biomarkers Market Assessment

• Blood-Based Biomarkers Market Segmentation
  • Blood-Based Biomarkers Market Segmentation By Type: Genetic Biomarkers, Protein Biomarkers, Cellular Biomarkers, Metabolite Biomarkers
  • Blood-Based Biomarkers Market Segmentation By Application: Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic and Other Diseases
  • Blood-Based Biomarkers Market Segmentation By Technology: Immunoassays, Polymerase Chain Reaction, Next-Generation Sequencing, Mass Spectrometry, Others
  • Blood-Based Biomarkers Market Segmentation By End Users: Hospital and Diagnostic Laboratories, Reference Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies
  • Blood-Based Biomarkers Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the blood-based biomarkers market are set to emerge as the trendsetter explore @ Blood-Based Biomarkers Market Analysis

Table of Contents 

Interested in knowing the blood-based biomarkers market share by 2034? Click to get a snapshot of the Blood-Based Biomarkers Market Size

Related Reports

Biomarkers Market

Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biomarkers companies such as F. Hoffmann-La Roche Ltd, Merck KGaA, Quibim, Quanterix, Abbott, QIAGEN, Revvity, Laboratory Corporation of America® Holdings, Charles River Laboratories., Bio-Rad Laboratories, Inc., Eurofins Scientific, BIOMÉRIEUX, Agilent Technologies, Inc., JSR Life Sciences, LLC, MESO SCALE DIAGNOSTICS, LLC., EKF Diagnostics, Celerion, Standard BioTools™, R-Biopharm AG, StressMarq Biosciences Inc., and others.

Cancer Biomarkers Market

Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., and others.

Digital Biomarkers Market

Digital Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key digital biomarkers companies such as BioSensics, AliveCor, Inc., Eyenuk, Inc., Quibim, Huma, Evidation Health, Inc., Oura Health Oy, Biobeat, Omada Health Inc., F. Hoffmann-La Roche Ltd., Koneksa Health, Altoida, Empatica Inc., VivoSense, IXICO plc, Proscia Inc., Agenus Inc., Lunit, BostonGene Corporation, PathAI, Inc., and others.

Alzheimer’s Disease Biomarkers Market

Alzheimer’s Disease Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Alzheimer’s disease biomarkers companies such as Fujirebio, Roche Diagnostics, Quanterix, Abbott Laboratories, Siemens Healthineers, Beckman Coulter Diagnostics, Sysmex Corporation, Revvity (PerkinElmer), Bio-Techne (R&D Systems), Thermo Fisher Scientific, Merck KGaA (Sigma-Aldrich), and others.

Neurological Biomarkers Market

Neurological Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurological biomarkers companies such as Abbott, Merck KGaA, Quanterix, Bio-Rad Laboratories, Inc., Banyan Biomarkers, Inc., Quanterix, Thermo Fisher Scientific, Fujirebio, Bio-Techne, ADx NeuroSciences NV, F. Hoffmann-La Roche Ltd., BIOMÉRIEUX, Siemens Healthineers, Quibim, C₂N Diagnostics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679